New approaches to strengthen pharmacovigilance

Drug Discovery Today: Technologies

Volumn 8, Issue 1, 2011, Pages

  Arlett, Peter R ^a   Kurz, Xavier ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; INFLUENZA VACCINE;

BAYES THEOREM; CASE STUDY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; HEART INFARCTION; HIP FRACTURE; HUMAN; INFLUENZA A (H1N1); INFORMATION PROCESSING; LIVER INJURY; META ANALYSIS; METHODOLOGY; NEOPLASM; OBSERVATIONAL STUDY; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; RISK BENEFIT ANALYSIS; STUDY DESIGN; SUICIDE;

EID: 80055001722     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2011.03.003     Document Type: Review

References (40)

1. Härmark, L. and van Grootheest, A.C. (2008) Pharmacovigilance: methods, recent developments and future perspectives. Eur. J. Clin. Pharmacol. 64, 743-752
2. Mann, R. and Andrews, E. (2007) Pharmacovigilance (2nd edn), Wiley
3. Waller, P.C. and Evans, S.J. (2003) A model for the future conduct of pharmacovigilance. Pharmacoepidemiol. Drug Saf. 12, 17-29 (Pubitemid 36192946)
4. Kurz, X. et al. (2010) The EudraVigilance database of spontaneous adverse reactions as a tool for H1N1 vaccine safety monitoring. Pharmacoepidemiol. Drug Saf. 19 (S), S330-S331
5. Blenkinsopp, A. et al. (2007) Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br. J. Clin. Pharmacol. 63, 148-156 (Pubitemid 46072099)
6. de Langen, J. et al. (2008) Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 31, 515-524 (Pubitemid 351693684)
7. Norwood, P.K. and Sampson, A.R. (1988) A statistical methodology for postmarketing surveillance of adverse drug reaction reports. Stat. Med. 7, 1023-1030
8. Evans, S.J. et al. (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483-486 (Pubitemid 34100774)
9. Bate, A. and Evans, S.J.W. (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol. Drug Saf. 18, 427-436
10. Hauben, M. (2004) Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics. Pharmacotherapy 24, 1122-1129 (Pubitemid 39128836)
11. Lindquist, M. et al. (1999) From association to alert - a revised approach to International Signal Analysis. Pharmacoepidemiol. Drug Saf. 8, S15-S25 (Pubitemid 29201771)
12. DuMouchel, W. and Pregibon, D. (2001) Empirical Bayes screening for multi-item associations. Proceedings of the Seventh ACM SIGKDD International conference on Knowledge Discovery and Data Mining pp. 67-76
13. Black, S. et al. (2009) Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 374, 2115-2122
14. Bryan, P. et al. (2010) H1N1 vaccine safety: real-time surveillance in the UK. Lancet 376, 417-418
15. Strom, B.L. (2005) Overview of automated databases in pharmacoepidemiology. In Pharmacoepidemiology (Strom, B.L., ed.), Wiley Chapter 13
16. Herret, E. (2010) Validation and validity of diagnoses in the General Practice Research Database (GPRD): a systematic review. Br. J. Clin. Pharmacol. 69, 4-14
17. Abenhaim, L. et al. (1996) for the International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 335, 609-616 (Pubitemid 26277950)
18. Roujeau, J.C. et al. (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333, 1600-1608
19. International Agranulocytosis and Aplastic Anemia Study, (1983) The design of a study of the drug etiology of agranulocytosis and aplastic anemia: a report from the International Agranulocytosis and Aplastic Anemia Study. Eur. J. Clin. Pharmacol. 24, 833-836
20. Kaufman, D.W. et al. (2001) Signal generation and clarification: use of case-control data. Pharmacoepidemiol. Drug Saf. 10, 197-203 (Pubitemid 32725360)
21. Butlen-Ducuing, F. et al. (2010) European Medicines Agency support mechanisms fostering orphan drug development. Drug News Perspect. 23, 71-81
22. Arlett, P.A. et al. (2007) A view from regulatory agencies. In Pharmacoepidemiology (Strom, B.L. and Pepper, G.S., eds), Wiley Chapter 8
23. Sturkenboom, M.C.J.M. (2008) Randomized studies in general practice databases. In Pharmacoepidemiology and Therapeutic Risk Management (Hartzema, A.G., Tilson, H.H., Chan, K.A., eds), Harvey Whitney Books Chapter 17
24. Giezen, T.J. et al. (2009) Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval. Drug Saf. 32, 1175-1187
25. Iskander, J. et al. (2005) Monitoring vaccine safety during an influenza pandemic. Yale J. Biol. Med. 78, 261-271
26. De Stefano, F. and Tokars, J. (2010) H1N1 vaccine safety monitoring: beyond background rates. Lancet 375, 1146-1147
27. Chen, R.T. et al. (2000) The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull. World Health Organ. 78, 186-194 (Pubitemid 30151603)
28. Vander Stichele, R.H. et al. (2004) European Surveillance of Antimicrobial Consumption (ESAC): data collection performance and methodological approach. Br. J. Clin. Pharmacol. 58, 419-428 (Pubitemid 39312466)
29. Martirosyan, L. et al. (2010) A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiol. Drug Saf. 19, 319-334
30. Valenciano, M. et al. (2011) Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 8, e1000388
31. Lesko, S.M. and Mitchell, A.A. (1995) Assessment of the safety of paediatric ibuprofen: a practitioner based randomised clinical trial. JAMA 279, 929-933
32. Strom, B.L. et al. (2011) Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am. J. Psychiatry 168, 193-201
33. Lesko, S.M. and Mitchell, A.A. (2005) The use of randomized controlled trials for pharmacoepidemiology Studies. In Pharmacoepidemiology (Strom, B.L., ed.), Wiley Chapter 39
34. Lau, J. et al. (1997) Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127, 820-826 (Pubitemid 27465551)
35. Glasziou, P.P. et al. (2002) Investigating causes of heterogeneity in systematic reviews. Stat. Med. 21, 1503-1511 (Pubitemid 34746059)
36. Hennessy, S. et al. (2001) Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 64, 125-133 (Pubitemid 33042599)
37. Chou, R. et al. (2005) Challenges in systematic reviews that assess treatment harms. Ann. Intern. Med. 142, 1090-1099 (Pubitemid 40847712)
38. Meier, C. et al. (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283, 3205-3210 (Pubitemid 30422037)
39. Van Staa, T.P. et al. (2001) Use of statins and risk of fractures. JAMA 285, 850-855
40. Schneeweiss, S. and Avorn, J. (2011) Postmarketing studies of drug safety. BMJ 342, d342